ArticleInternational journal of obesity (2005)2021

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.

Sean Wharton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.